EU/3/17/1912

About

On 23 August 2017, orphan designation (EU/3/17/1912) was granted by the European Commission to Vivus B.V., the Netherlands, for tacrolimus for the treatment of pulmonary arterial hypertension.

Key facts

Active substance
tacrolimus
Medicine name
-
Disease / condition
Treatment of pulmonary arterial hypertension
Date of first decision
23/08/2017
Outcome
Positive
EU designation number
EU/3/17/1912

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Vivus B.V.
Prins Bernhardplein 200
1097 JB Amsterdam
The Netherlands
Tel. +31 20 5214777
E-mail: varghese@vivus.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating